[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ferring Pharmaceuticals\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":161},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,63,88,116,141],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100555306","phase-3-trial-of-nadofaragene-firadenovec-vs-observation-in-participants-with-intermediate-risk-non-muscle-invasive-bladder-cancer-100555306",false,"NCT06510374","Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer","A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer","ABLE-32","Inclusion Criteria:\n\n* Diagnosed with intermediate risk non-muscle invasive bladder cancer (IR NMIBC) as defined by American Urological Association (AUA)\u002FSociety of Urologic Oncology \\[SUO\\] Guideline (2020)\n* Has undergone adequate transurethral resection of bladder tumor (TURBT; with or without peri-operative chemotherapy) within 60 days prior to randomization:\n\n  * Recurrence within 1 year, low-grade Ta\n  * Solitary low-grade Ta \\>3 cm\n  * Low-grade Ta, multifocal\n  * Solitary high-grade Ta, ≤3 cm\n  * Low-grade T1\n\n    * Patients with T1 disease should undergo resection at the base of the lesion and biopsies should contain muscle fibres.\n    * Restage TURBT may be done at the discretion of the investigator\n\nExclusion Criteria:\n\n* Current or previous evidence of muscle invasive (muscularis propria) or metastatic disease presented at the screening visit\n\nHigh risk NMIBC defined as:\n\n* High-grade T1\n* Any recurrent, high-grade Ta\n* High-grade Ta \\>3 cm (or multifocal)\n* Any carcinoma in situ (CIS)\n* Any Bacillus Calmette-Guérin (BCG) failure in high-grade subject\n* Any variant histology\n* Any prostatic urethral involvement\n\nLow risk NMIBC defined as:\n\n* First occurrence of low-grade solitary Ta ≤3 cm\n* Recurrence of low-grade solitary Ta ≤3 cm \\>12 months from previous occurrence\n* Papillary urothelial neoplasm of low malignant potential","ALL","18 Years",{"count":20,"type":21},454,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)",[27],"Intermediate Risk Non-Muscle Invasive Bladder Cancer","RECRUITING","2026-06-29",{"date":31,"type":32},"2026-07-01","ACTUAL",{"date":34,"type":32},"2024-10-01",{"date":36,"type":21},"2031-06-30",{"name":38,"class":39},"Ferring Pharmaceuticals","INDUSTRY",102,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},"100558041","phase-3-a-trial-to-evaluate-intravesical-nadofaragene-firadenovec-alone-or-in-combination-with-chemotherapy-or-immunotherapy-in-participants-with-high-grade-bcg-unresponsive-non-muscle-invasive-bladder-cancer-100558041","NCT06545955","A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","A Phase 3, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)","ABLE-22","Inclusion Criteria:\n\n* Diagnosed, as documented, with carcinoma in situ (CIS) ±Ta\u002FT1 high-grade disease.\n\n  * For T1 disease biopsies should contain muscle fibres.\n* Unresponsive to ≥2 courses of Bacillus Calmette-Guerin (BCG) therapy within the last 12 months. BCG-unresponsive refers to participants with high-grade non-muscle invasive bladder cancer (NMIBC) who are unlikely to benefit from and who will not be receiving further intravesical BCG. The term \"BCG-Unresponsive\" includes participants who did not respond to BCG treatment and have a persistent high-grade recurrence within 12 months after BCG was initiated, and those who despite an initial complete response to BCG, relapse with CIS within 12 months of their last intravesical treatment with BCG or relapse with high-grade Ta\u002FT1 NMIBC within 6 months of their last intravesical treatment with BCG. The following criteria define the participants who may be included in the trial:\n\n  * Have received at least 2 courses of BCG within a 12 month period - defined as at least 5 of 6 induction BCG instillations and at least 2 of 3 instillations of maintenance BCG, or at least 2 of 6 instillations of a second induction course, where maintenance BCG is not given.\n\n    o Exception: those who have T1 high-grade disease at 1st evaluation after induction BCG alone (at least 5 of 6 doses) may qualify in the absence of disease progression\n  * At the time of tumour recurrence, participants with CIS alone or high-grade Ta\u002FT1 with CIS should be within 12 months of last exposure to BCG\n  * No maximum limit to the amount of BCG administered\n  * All visible papillary tumours must be resected and those with persistent T1 disease on transurethral resection of bladder tumour (TURBT) should undergo an additional re-TURBT within 14 to 70 days prior to beginning trial treatment. Obvious areas of CIS should also be fulgurated\n* Eastern Cooperative Oncology Group (ECOG) status ≤2\n* Aged ≥18 years at the time of consent\n* Available for the whole duration of the trial\n* Life expectancy \\>2 years, in the opinion of the investigator\n* Absence of concomitant upper tract urothelial carcinoma or urothelial carcinoma within the prostatic urethra. Freedom from upper tract disease (if clinically indicated) as indicated by no evidence of upper tract tumour by either intravenous pyelogram, retrograde pyelogram, computed tomography (CT) scan with or without urogram, or magnetic resonance imaging (MRI) with or without urogram performed within 6 months of enrolment. Absence of locally advanced disease as assessed by CT scan or MRI\n* Participants who elect not to undergo cystectomy\n* Participants with prostate cancer on active surveillance at low risk for progression are permitted to be included into the trial at the discretion of the investigator\n* Females of reproductive potential must have a negative highly sensitive urine or serum pregnancy test upon entry into this trial and be willing to use highly effective contraception during treatment with the investigational medicinal product and for 6 months following the last dose. Otherwise, female participants must be post-menopausal (no menstrual period for a minimum of 12 months, as confirmed by follicle-stimulating hormone levels) or surgically sterile\n* Male subjects must be willing to use a male condom and effective contraception during sex throughout the treatment period and for 3 months following the last dose.\n\nExclusion Criteria:\n\n* Current or previous evidence of muscle-invasive (muscularis propria) or metastatic disease presented at the screening visit. Examples of increased risk of muscle-invasive disease include but are not limited to:\n\n  * Presence of lymphovascular invasion and \u002F or micropapillary, sarcomatoid, plasmacytoid and \u002F or neuroendocrine disease as shown in the histology of the biopsy sample\n  * Participants with CIS+T1 disease accompanied by the presence of hydronephrosis secondary to the primary tumour\n* Current systemic therapy for bladder cancer other than investigational medicinal products used in randomisation arm\n* Current or prior investigational treatment for BCG-unresponsive NMIBC or any other investigational drug (drug used in a clinical trial, i.e drug used in a Ferring sponsored non interventional study does not apply) within 1 month prior to screening\n* Current or prior pelvic external beam radiotherapy within 2 years of screening\n* Prior treatment with nadofaragene firadenovec at any time\n* Prior systemic therapy for bladder cancer at any time\n* Prior intravesical chemotherapy for the treatment of BCG-unresponsive NMIBC",{"count":50,"type":21},250,[24],"The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta\u002FT1 achieved a complete response (CR) at 3 months. In this trial, the safety and efficacy of intravesical instillation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy will be evaluated in participants with NMIBC CIS (± high-grade Ta\u002FT1).",[54],"Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","2026-06-15",{"date":57,"type":32},"2026-06-17",{"date":34,"type":32},{"date":60,"type":21},"2030-12-31",{"name":38,"class":39},75,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},"100567461","phase-1-low-grade-utuc-treated-with-nadofaragene-firadenovec-administered-to-renal-pelvis-100567461","NCT06668493","Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis","A Phase 1\u002F2, Single-arm, Open-Label Trial to Evaluate the Safety and Efficacy of Nadofaragene Firadenovec Instilled to the Renal Pelvis in Adult Subjects With Low-grade Upper Tract Urothelial Carcinoma (LG-UTUC)","LUNAR","Inclusion Criteria:\n\n1. Aged ≥18 years at the time of signing informed consent.\n2. Able to give written informed consent.\n3. Have biopsy-proven low-grade upper tract urothelial cancer (LG-UTUC) confirmed by a pathology report ≤2 months prior to enrolment.\n4. Have ≥1 measurable papillary low-grade tumour (5-15 mm in maximum diameter), evaluated visually above the ureteropelvic junction before enrolment.\n\n   * Subjects with low-grade tumour larger than 15 mm will be eligible if endoscopic downsizing of the tumour to 5-15 mm in maximum diameter has been performed before enrolment.\n5. Willing to be available for at least 18 months after first dosing.\n6. Have life expectancy \\>2 years, in the opinion of the investigator.\n7. Have an Eastern Cooperative Oncology Group (ECOG) status of 2 or less.\n8. Females of reproductive potential must have a negative highly sensitive urine or serum pregnancy test upon entry into this trial and be willing to use highly effective contraception during treatment with the investigational medicinal product (IMP) and for 6 months following the last dose. Otherwise, female subjects must be postmenopausal (no menstrual period for a minimum of 12 months) or surgically sterile. Highly effective methods of contraception include: combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner, and sexual abstinence.\n9. Male subjects with female partners of reproductive potential must be surgically sterile or willing to use a condom in addition to effective contraception in their female partner during treatment with the IMP and for 3 months following the last dose.\n10. Adequate laboratory values:\n\n    * haemoglobin ≥10 g\u002FdL\n    * white blood cells (WBC) ≥4000\u002FμL\n    * absolute neutrophil count (ANC) ≥2000\u002FμL\n    * platelet count ≥100,000\u002FμL\n    * international normalized ratio (INR)\\* below institutional upper limit of normal (ULN)\n    * activated partial thromboplastin time (aPTT)\\* below institutional ULN\n    * aspartate aminotransferase (AST) ≤1.5 x ULN\n    * alanine aminotransferase (ALT) ≤1.5 x ULN\n    * total bilirubin ≤1.5 x ULN\n    * sodium \\>135 mmol\u002FL\n    * potassium between 3.6 and 5.0 mmol\u002FL\n11. Have an estimated glomerular filtration rate (eGFR) ≥45 mL\u002Fmin\u002F1.73 m2 (for inclusion in the safety lead-in the eGFR must be ≥60 mL\u002Fmin\u002F1.73 m2 \\[see exclusion criteria #20\\]).\n\nExclusion Criteria:\n\n1. UTUC characterised by one or more of the following:\n\n   * High-grade cytology or high-grade histology\n   * Multi-focal UTUC\n\n     * Exception: Subjects with low-grade multi-focal tumours will be eligible if any ureteral tumours can be ablated before enrolment and if the total diameter of the multifocal tumours above the ureteropelvic junction is not exceeding 15 mm in diameter.\n   * Bilateral disease\n\n     * Exception: Subjects who have had bilateral disease are eligible (not in the safety lead-in) if one renal unit is removed or rendered disease-free by endoscopic ablation before enrolment.\n2. Current or previous evidence of carcinoma in situ, of muscle invasive (muscularis propria) urothelial cancer in the urogenital tract presented at the screening visit.\n3. Concomitant lower tract urothelial carcinoma and\u002For concomitant or prior urothelial carcinoma within the prostatic urethra.\n4. History of high grade papillary urothelial cancer within 2 years prior to screening.\n5. Current or prior treatment with mitomycin gel and\u002For any investigational drug for the treatment of UTUC.\n6. Current systemic chemo- or immunotherapy for bladder cancer or any other malignancy.\n7. Current or prior investigational treatment for Bacillus Calmette-Guerin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) or any other investigational drug within 1 month prior to screening.\n8. Current or prior retroperitoneal external beam radiotherapy within 5 years of screening.\n9. Prior treatment with adenovirus-based drugs including use of other adenovirus vector medications, including COVID-19 vaccines, within 2 weeks before instillation.\n10. Suspected and\u002For a medical history of hypersensitivity to nadofaragene firadenovec, interferon-α2b (IFN-α2b) and\u002For adenovector medications.\n11. Urinary tract infection or bacterial cystitis (once satisfactorily treated, subjects can enter the trial).\n12. Clinically significant and unexplained elevated liver or renal function tests at screening.\n13. Women who are pregnant (highly sensitive urine or serum pregnancy test at screening) or breastfeeding.\n14. Any other significant disease or other clinical findings which in the opinion of the investigator would prevent trial entry.\n15. History of malignancy in any other organ system than the upper urinary tract within the past 5 years prior to screening. However, subjects with the following exceptions will be allowed inclusion in the trial:\n\n    * Treated basal cell carcinoma or squamous cell carcinoma of the skin.\n    * History of ≤pT2 upper tract urothelial carcinoma, at least 24 months after radical nephroureterectomy (RNU).\n    * Cervical intraepithelial carcinoma (CIN) without evidence of invasive carcinoma.\n    * Prostate cancer that is under active surveillance or urothelial cancer. All other genitourinary cancers are excluded.\n16. Inability to deliver IMP to the pyelocaliceal system.\n17. Previous BCG treatment during 6 months before the initiation of treatment.\n18. Any immunosuppressive therapy within 3 months prior to screening.\n19. Subjects who are immunocompromised or immunodeficient at screening.\n20. Subjects with solitary kidney and\u002For an eGFR \\\u003C60 mL\u002Fmin\u002F1.73 m2 (only applicable for subjects in the safety lead-in period).",{"count":72,"type":21},20,[74,75],"PHASE1","PHASE2","The primary purpose of this trial is to evaluate the safety \\& tolerability of Nadofaragene Firadenovec in subjects with LG-UTUC. To help with this evaluation, a safety lead-in period will be conducted for the first 6 subjects. Complete response is at 3 or 6 months defined as absence of any UTUC in the renal pelvis.",[78],"Low-grade Upper Tract Urothelial Carcinoma","2026-05-06",{"date":81,"type":32},"2026-05-08",{"date":83,"type":32},"2025-06-12",{"date":85,"type":21},"2029-11-30",{"name":38,"class":39},9,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},"100371208","phase-1-study-assessing-clenpiq-as-bowel-preparation-for-pediatric-colonoscopy-100371208","NCT04113382","Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy","A Randomized, Assessor-Blind, Parallel-Groups, Multicenter Trial Assessing the Safety and Efficacy, Including Pharmacokinetic Assessments, of CLENPIQ in Children Aged 2 Years to Less Than 9 Years","PICCOLO","Inclusion Criteria:\n\n* Male or female, aged 2 years to \\\u003C9 years being scheduled to undergo elective colonoscopy.\n* Weight ≥10 kg (≥22 lbs).\n* Participants must have had an average of three or more spontaneous bowel movements (SBM) per week for 1 month prior to the colonoscopy.\n* Written informed consent (by parent(s)\u002F caregiver(s)\u002F guardian(s)) and assent (if applicable) obtained at screening.\n\nExclusion Criteria:\n\n* History of significant liver, cardiovascular, or renal disease (including recent or ongoing oliguria).\n* Acute surgical abdominal conditions (e.g., acute obstruction or perforation) during the screening period.\n* Clinically significant abdominal pain during the screening period.\n* Severe acute inflammatory bowel disease (IBD) during the screening period.\n* Any prior colorectal surgery, excluding appendectomy and polyp removal.\n* History of colon disease (e.g., Hirschsprung disease, volvulus, idiopathic pseudo-obstruction, or hypomotility syndrome).\n* History of or ongoing intestinal ulceration, toxic megacolon or other toxic colitis.\n* History of upper gastrointestinal disorder (e.g., active ulcer, pyloric stenosis or other cause of gastric retention, gastroparesis, or ileus).\n* History of upper gastrointestinal surgery (e.g., gastric resection or gastric bypass), excluding cholecystectomy.\n* Chronic or persistent, severe nausea or vomiting during the screening period.\n* Moderate to severe dehydration during the screening period.\n* Prior history of epileptic reaction, convulsions, or seizures.\n* Any clinically relevant neurological events with or without association with hyponatremia during the screening period.\n* Serum creatinine, estimated glomerular filtration rate (eGFR), potassium, or sodium outside normal limits during the screening period.\n* Hypermagnesemia during the screening period.\n* Use of the following prohibited medication: lithium (within 48 hours prior to procedure), laxatives (within 24 hours prior to procedure), drugs that in the opinion of the investigator are causing constipation in the participant (within 48 hours prior to procedure), antidiarrheal drugs (within 72 hours prior to procedure), or oral iron preparations (within 1 week prior to procedure).\n* Participation in an interventional investigational trial requiring administration of an investigational drug within 30 days prior to receiving trial medication (or within 60 days for investigational drugs with an elimination half-life \\>15 days).\n* Any clinically relevant abnormal findings in medical history, physical examination, vital signs, electrocardiogram (ECG), clinical chemistry, hematology, coagulation, or urinalysis at screening which in the opinion of the investigator(s), might put the participant at risk because of his\u002Fher participation in the trial.\n* Hypersensitivity to any of the ingredients of the trial medications.\n* Inability to comply with the dietary restrictions in the trial or the fluid requirements before and after investigational medicinal product (IMP) administration.","2 Years","8 Years",{"count":99,"type":21},30,[74,75],"Bowel preparation for pediatric colonoscopy.",[103],"Bowel Preparation",[105,106],"Colon Cleansing","Preparation for Colonoscopy","2026-04-08",{"date":109,"type":32},"2026-04-09",{"date":111,"type":32},"2022-06-23",{"date":113,"type":21},"2027-06",{"name":38,"class":39},5,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":124,"minAge":125,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":128,"phases":4,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},"100595207","to-investigate-rekovelle-in-chinese-women-undergoing-assisted-reproductive-technologies-effectiveness-safety-and-patterns-of-use-in-real-world-practice-100595207","NCT07029451","To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world Practice","Prospective, Post-authorisation, Multi-centre, Non-interventional Study to Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world Practice","LYCHEE","Inclusion Criteria:\n\n* Women who meet all the following criteria are eligible for participation:\n\n  * At least 20 years of age (including the 20th birthday) when signing informed consent\n  * Prescribed REKOVELLE for the first time in controlled ovarian stimulation for in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycles\n  * Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Women who meet any of the following criteria are not eligible for participation:\n\n  * Previously undergone more than 1 controlled ovarian stimulation cycles for IVF or ICSI\n  * Currently participating in an interventional clinical study for which treatment with medication is mandated\n  * Currently undergoing ovarian stimulation for fertility preservation or oocytes donation\n  * Contraindications for the use of REKOVELLE","FEMALE","20 Years",{"count":127,"type":21},2500,"OBSERVATIONAL","This is a multi-centre prospective non-interventional trial to assess the pattern of use of REKOVELLE® in Women Undergoing In Vitro Fertilisation (IVF) or Intracytoplasmic Sperm Injection (ICSI) Procedures in Routine Clinical Practice.\n\nThere will be approximately 2500 patients initiated with REKOVELLE® treatment and enrolled in 30-50 sites in China. The total duration of the study will be approximately 35 months.",[131],"Infertility","2026-01-16",{"date":134,"type":32},"2026-01-20",{"date":136,"type":32},"2025-08-05",{"date":138,"type":21},"2028-09-30",{"name":38,"class":39},28,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":124,"minAge":4,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":128,"phases":4,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":160},"100558035","rekovelle-pen-for-sc-injection-general-drug-use-survey-controlled-ovarian-stimulation-in-assisted-reproductive-technologies-100558035","NCT06545877","REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies)","REKOVELLE® PEN S.C. Injection 12μg\u002F36μg\u002F72μg for Controlled Ovarian Stimulation in Assisted Reproductive Technologies - General Drug Use-results Survey","Inclusion Criteria:\n\n* Participants who received the REKOVELLE in controlled ovarian stimulation in assisted reproductive technologies and have consented to participate in the survey.\n\nExclusion Criteria:\n\n* No exclusion criteria because data are collected under conditions of use in daily practice.",{"count":149,"type":21},500,"This survey targets controlled ovarian stimulation with this drug for the development of multiple oocytes in women undergoing assisted reproduction (ART) such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).",[131],"2025-08-14",{"date":154,"type":32},"2025-08-20",{"date":156,"type":32},"2022-09-16",{"date":158,"type":21},"2029-06-22",{"name":38,"class":39},1,""]